GALMED PHARMACEUTICALS LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3711 USD | -4.21% |
|
-4.72% | -18.44% |
Presenter SpeechSara Parigian (Attendees)Good afternoon and welcome to the Galmed KOL Symposiu...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).
Calendar
2025-05-06
- Q1 2025 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.3711
USD
Average target price
1
USD
Spread / Average Target
+169.47%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.44% | 2.23M | |
| +9.83% | 115B | |
| +10.80% | 105B | |
| -10.84% | 22.71B | |
| -1.69% | 21.83B | |
| -10.23% | 18.18B | |
| -41.92% | 16.52B | |
| -15.11% | 16.01B | |
| +6.62% | 14.14B | |
| +17.53% | 10.71B |
- Stock Market
- Equities
- GLMD Stock
- News Galmed Pharmaceuticals Ltd.
- Transcript : Galmed Pharmaceuticals Ltd. - Special Call
